Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vasopressin V1a and V1b receptors are G protein-coupled receptors (GPCRs) that mediate the physiological effects of arginine vasopressin (AVP) through the Gq/11 signaling pathway. The V1a receptor (AVPR1A) is predominantly found in vascular smooth muscle, where it induces vasoconstriction, and in the brain, where it modulates complex social behaviors and emotional regulation (UniProt P37288). The V1b receptor (AVPR1B), often referred to as the V3 receptor, is primarily expressed in the anterior pituitary and plays a critical role in the stress response by stimulating the secretion of adrenocorticotropic hormone (ACTH) (PubMed: 11906001). These receptors are significant therapeutic targets for cardiovascular conditions like heart failure and hyponatremia, as well as neuropsychiatric disorders including anxiety, depression, and autism spectrum disorder (PubMed: 25833129). Drugs interacting with these receptors include conivaptan, a dual V1a/V2 antagonist used for hyponatremia, and selective antagonists like relcovaptan (V1a) and nelivaptan (V1b) (PubChem CID 443871). Clinical management of these targets requires careful monitoring of blood pressure and electrolyte balance due to their potent effects on vascular tone and the HPA axis (StatPearls: Vasopressin). Research continues into the role of V1a in social communication deficits, with agents like balovaptan being investigated for autism (PubMed: 30655495).
Drugs targeting these receptors typically act as antagonists to block the binding of arginine vasopressin, thereby inhibiting the Gq-protein signaling pathway. This results in decreased vascular resistance (V1a) and reduced secretion of adrenocorticotropic hormone (V1b). Conversely, agonists like terlipressin activate these receptors to induce vasoconstriction for the treatment of conditions like hepatorenal syndrome.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arginine vasopressin receptor 1A (AVPR1A) and Arginine vasopressin receptor 1B (AVPR1B) (AVPR1A/AVPR1B).